<![CDATA[Boehringer Ingelheim 보도자료 - 뉴스와이어]]>https://www.newswire.co.kr/?md=A10&act=article&no=24113>Tue, 28 Apr 2026 10:16:49 +0900Copyright (c) 2004~2026 Korea Newswire All rights reservedko-KR<![CDATA[Boehringer Ingelheim receives approval for SENVELGO® in Europe: the first oral liquid medication for diabetic cats]]>https://www.newswire.co.kr/newsRead.php?no=979590Sun, 26 Nov 2023 13:59:45 +0900<![CDATA[Boehringer Ingelheim expands immuno-oncology portfolio with the acquisition of bacterial cancer therapy specialist T3 Pharma]]>https://www.newswire.co.kr/newsRead.php?no=979394Thu, 23 Nov 2023 09:50:00 +0900<![CDATA[Boehringer Ingelheim achieves major milestone in chronic kidney disease: aldosterone synthase inhibitor on top of empagliflozin delivers promising results in Phase II trial]]>https://www.newswire.co.kr/newsRead.php?no=977993Sun, 05 Nov 2023 10:20:00 +0900<![CDATA[Boehringer Ingelheim’s SPEVIGO® (spesolimab) wins 2023 Prix Galien USA Best Orphan/Rare Diseases Solution Award]]>https://www.newswire.co.kr/newsRead.php?no=977399Fri, 27 Oct 2023 17:27:50 +0900<![CDATA[Phase III Studies to Investigate Survodutide for People Living with Obesity and Overweight, with and without Diabetes, Cardiovascular Disease and Chronic Kidney Disease]]>https://www.newswire.co.kr/newsRead.php?no=975850Mon, 09 Oct 2023 15:05:00 +0900<![CDATA[Boehringer Ingelheim and ZEISS join forces to early detect eye diseases and prevent vision loss]]>https://www.newswire.co.kr/newsRead.php?no=975488Tue, 03 Oct 2023 11:27:21 +0900<![CDATA[Boehringer Ingelheim receives SBTi validation for CO2 reduction targets]]>https://www.newswire.co.kr/newsRead.php?no=974441Thu, 14 Sep 2023 17:18:17 +0900<![CDATA[First half of 2023: Boehringer Ingelheim sees strong growth and expansion in key therapy areas]]>https://www.newswire.co.kr/newsRead.php?no=971645Tue, 01 Aug 2023 16:24:28 +0900<![CDATA[Jardiance® (empagliflozin) approved in the EU for the treatment of adults with chronic kidney disease]]>https://www.newswire.co.kr/newsRead.php?no=971243Wed, 26 Jul 2023 10:45:00 +0900<![CDATA[Spesolimab prevents generalized pustular psoriasis flares in EFFISAYIL™ 2 trial]]>https://www.newswire.co.kr/newsRead.php?no=969989Tue, 04 Jul 2023 16:25:57 +0900<![CDATA[Data shows nearly 19% weight loss in people with overweight or obesity in Boehringer Ingelheim and Zealand Pharma Phase II trial with survodutide (BI 456906)1]]>https://www.newswire.co.kr/newsRead.php?no=969386Sun, 25 Jun 2023 13:26:19 +0900<![CDATA[Jardiance® recommended for the treatment of adults with chronic kidney disease in the EU]]>https://www.newswire.co.kr/newsRead.php?no=969380Sun, 25 Jun 2023 10:56:21 +0900<![CDATA[Boehringer Ingelheim and Zealand Pharma announce phase II trial showed 14.9% weight loss in people living with obesity or overweight]]>https://www.newswire.co.kr/newsRead.php?no=966676Wed, 10 May 2023 17:22:34 +0900<![CDATA[Boehringer Ingelheim Begins Clinical Development of First-In-Class Treatment for Fibrotic Diseases]]>https://www.newswire.co.kr/newsRead.php?no=966665Wed, 10 May 2023 15:40:00 +0900<![CDATA[SPEVIGO® granted Breakthrough Therapy Designation in the U.S. for the prevention of generalized pustular psoriasis flares]]>https://www.newswire.co.kr/newsRead.php?no=966298Wed, 03 May 2023 14:00:00 +0900<![CDATA[Boehringer Ingelheim reaches more patients than ever in 2022 as innovative medicines drive growth]]>https://www.newswire.co.kr/newsRead.php?no=964153Wed, 29 Mar 2023 17:16:33 +0900<![CDATA[Spesolimab meets primary and key secondary endpoint for prevention of generalized pustular psoriasis flares]]>https://www.newswire.co.kr/newsRead.php?no=960534Mon, 30 Jan 2023 17:30:00 +0900<![CDATA[Mental health focus makes Boehringer Ingelheim stand out as Global Top Employer 2023]]>https://www.newswire.co.kr/newsRead.php?no=959937Wed, 18 Jan 2023 09:20:00 +0900<![CDATA[Boehringer Ingelheim and 3T Biosciences Join Forces to Develop Next-Generation Cancer Immunotherapies]]>https://www.newswire.co.kr/newsRead.php?no=959468Tue, 10 Jan 2023 09:55:00 +0900<![CDATA[Boehringer Ingelheim announces appointments to Board of Managing Directors]]>https://www.newswire.co.kr/newsRead.php?no=958410Wed, 21 Dec 2022 09:45:00 +0900<![CDATA[Boehringer Ingelheim and Click Therapeutics expand their existing Collaboration to develop Prescription Digital Therapeutics for Schizophrenia]]>https://www.newswire.co.kr/newsRead.php?no=958307Tue, 20 Dec 2022 10:05:00 +0900<![CDATA[European Commission approves SPEVIGO® (spesolimab) for generalized pustular psoriasis flares]]>https://www.newswire.co.kr/newsRead.php?no=957898Wed, 14 Dec 2022 14:25:00 +0900<![CDATA[Phase III trial demonstrated Jardiance is the first SGLT2 inhibitor to show statistically significant reduction in blood sugar levels in children and adolescents with type 2 diabetes]]>https://www.newswire.co.kr/newsRead.php?no=957436Thu, 08 Dec 2022 09:40:00 +0900<![CDATA[Landmark EMPA-KIDNEY trial showed significant benefit of Jardiance® in reducing kidney disease progression or cardiovascular death by 28% vs. placebo in people with chronic kidney disease]]>https://www.newswire.co.kr/newsRead.php?no=954964Mon, 07 Nov 2022 11:50:00 +0900<![CDATA[University of Tübingen and Boehringer Ingelheim Join Forces to Lead AI and Data Science R&D for New Medical Breakthroughs]]>https://www.newswire.co.kr/newsRead.php?no=953914Fri, 21 Oct 2022 10:40:00 +0900